Last reviewed · How we verify
Routine three-drug antiretroviral prophylaxis
A combination of three antiretroviral drugs that work together to suppress HIV replication by targeting different stages of the viral lifecycle.
A combination of three antiretroviral drugs that work together to suppress HIV replication by targeting different stages of the viral lifecycle. Used for HIV post-exposure prophylaxis (PEP), HIV pre-exposure prophylaxis (PrEP), HIV treatment.
At a glance
| Generic name | Routine three-drug antiretroviral prophylaxis |
|---|---|
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Antiretroviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Routine three-drug antiretroviral prophylaxis typically combines agents from different drug classes (such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or integrase inhibitors) to prevent HIV infection through complementary mechanisms. This multi-drug approach reduces the likelihood of viral resistance and provides more potent suppression of HIV replication than monotherapy.
Approved indications
- HIV post-exposure prophylaxis (PEP)
- HIV pre-exposure prophylaxis (PrEP)
- HIV treatment
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Lipid abnormalities
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: